Cost effectiveness of alendronate (fosamax) for the treatment of osteoporosis and prevention of fractures.
(2003) In PharmacoEconomics 21(5). p.305-314
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/114334
- author
- Johnell, Olof LU ; Jönsson, Bengt ; Jönsson, Linus and Black, Dennis
- organization
- publishing date
- 2003
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Postmenopausal: drug therapy, Postmenopausal: economics, Osteoporosis, Time Factors, Sweden, Postmenopausal: mortality, Quality of Life, Quality-Adjusted Life Years, Support, Non-U.S. Gov't, Age Factors, Aged, Alendronate: economics, Alendronate: therapeutic use, Cohort Studies, Cost-Benefit Analysis, Female, Fractures: economics, Fractures: prevention & control, Human, Markov Chains
- in
- PharmacoEconomics
- volume
- 21
- issue
- 5
- pages
- 305 - 314
- publisher
- Adis International
- external identifiers
-
- wos:000182092500002
- pmid:12627984
- scopus:0037253242
- ISSN
- 1179-2027
- language
- English
- LU publication?
- yes
- id
- 00e59db2-b386-42ef-b142-cd0f5878f509 (old id 114334)
- alternative location
- http://www.ingentaconnect.com/content/adis/pec/2003/00000021/00000005/art00002
- date added to LUP
- 2016-04-01 15:17:46
- date last changed
- 2024-05-23 11:36:31
@article{00e59db2-b386-42ef-b142-cd0f5878f509, author = {{Johnell, Olof and Jönsson, Bengt and Jönsson, Linus and Black, Dennis}}, issn = {{1179-2027}}, keywords = {{Postmenopausal: drug therapy; Postmenopausal: economics; Osteoporosis; Time Factors; Sweden; Postmenopausal: mortality; Quality of Life; Quality-Adjusted Life Years; Support; Non-U.S. Gov't; Age Factors; Aged; Alendronate: economics; Alendronate: therapeutic use; Cohort Studies; Cost-Benefit Analysis; Female; Fractures: economics; Fractures: prevention & control; Human; Markov Chains}}, language = {{eng}}, number = {{5}}, pages = {{305--314}}, publisher = {{Adis International}}, series = {{PharmacoEconomics}}, title = {{Cost effectiveness of alendronate (fosamax) for the treatment of osteoporosis and prevention of fractures.}}, url = {{http://www.ingentaconnect.com/content/adis/pec/2003/00000021/00000005/art00002}}, volume = {{21}}, year = {{2003}}, }